Clinical Trial Results:
Treatment of patients with Nephrogenic Systemic Fibrosis(NSF) with Imatinib Mesylate(Glivec). An open label clinical trial among patients with moderate to severe NSF.
Summary
|
|
EudraCT number |
2009-013295-48 |
Trial protocol |
DK |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
19 Nov 2021
|
First version publication date |
19 Nov 2021
|
Other versions |
|
Summary report(s) |
A little antifibrotic effect of low-dose imatinib mesylate in patients with nephrogenic systemic fibrosis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.